ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,969.34
0.35%
Dow Jones
44,296.51
0.97%
US Dollar vs MXN
20.3873
-0.20%
Brent Oil
74.355
-0.56%
Bitcoin
98,794.09
0.76%
Pepperstone
Advertisement
Registration Strip Icon for default Regístrate gratis para obtener cotizaciones en tiempo real, gráficos interactivos, flujo de opciones en vivo y más.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Centessa Pharmaceuticals PLC (CNTA)

  7. Centessa Pharmaceuticals PLC (CNTA) Noticias

CNTA

Centessa Pharmaceuticals (CNTA)

Centessa Pharmaceuticals PLC
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:CNTA
FechaHoraFuenteTítuloSímboloCompañía
22/11/202416:06Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CNTACentessa Pharmaceuticals PLC
22/11/202415:03Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:CNTACentessa Pharmaceuticals PLC
12/11/202406:16Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:CNTACentessa Pharmaceuticals PLC
12/11/202406:08Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CNTACentessa Pharmaceuticals PLC
12/11/202406:00GlobeNewswire Inc.Centessa Pharmaceuticals Reports Financial Results for the Third Quarter of 2024 and Provides Business UpdateNASDAQ:CNTACentessa Pharmaceuticals PLC
04/11/202406:30GlobeNewswire Inc.Centessa Pharmaceuticals to Participate in Upcoming Investor ConferencesNASDAQ:CNTACentessa Pharmaceuticals PLC
18/10/202415:01Edgar (US Regulatory)Form 10-Q/A - Quarterly report [Sections 13 or 15(d)]: [Amend]NASDAQ:CNTACentessa Pharmaceuticals PLC
26/09/202405:00GlobeNewswire Inc.Centessa Pharmaceuticals Presents Preclinical Data for ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist, at the 27th Congress of the European Sleep Research Society (Sleep Europe 2024)NASDAQ:CNTACentessa Pharmaceuticals PLC
13/09/202415:02Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:CNTACentessa Pharmaceuticals PLC
12/09/202421:34GlobeNewswire Inc.Centessa Pharmaceuticals Announces Pricing of Upsized $225,000,000 Public Offering of American Depositary SharesNASDAQ:CNTACentessa Pharmaceuticals PLC
11/09/202415:04GlobeNewswire Inc.Centessa Pharmaceuticals Announces $150,000,000 Proposed Public Offering of American Depositary SharesNASDAQ:CNTACentessa Pharmaceuticals PLC
11/09/202415:01Edgar (US Regulatory)Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuersNASDAQ:CNTACentessa Pharmaceuticals PLC
10/09/202406:00GlobeNewswire Inc.Centessa Announces Positive Interim Phase 1 Clinical Data with its Novel Orexin Receptor 2 (OX2R) Agonist, ORX750, in Acutely Sleep-Deprived Healthy VolunteersNASDAQ:CNTACentessa Pharmaceuticals PLC
27/08/202407:00GlobeNewswire Inc.Centessa Pharmaceuticals Announces Late-Breaking Poster Presentation of Non-Human Primate Data for ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist, at the 27th Congress of the European Sleep Research Society (Sleep Europe 2024)NASDAQ:CNTACentessa Pharmaceuticals PLC
21/08/202407:00GlobeNewswire Inc.Centessa Pharmaceuticals to Participate in the Morgan Stanley 22nd Annual Global Healthcare ConferenceNASDAQ:CNTACentessa Pharmaceuticals PLC
13/08/202406:00GlobeNewswire Inc.Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Second Quarter of 2024NASDAQ:CNTACentessa Pharmaceuticals PLC
10/06/202406:00GlobeNewswire Inc.Centessa Pharmaceuticals Strengthens Executive Leadership with Appointment of John Crowley CPA, as Chief Financial Officer and Gregory Weinhoff MD MBA, as Chief Business OfficerNASDAQ:CNTACentessa Pharmaceuticals PLC
13/05/202415:10GlobeNewswire Inc.Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the First Quarter of 2024NASDAQ:CNTACentessa Pharmaceuticals PLC
09/05/202407:01Edgar (US Regulatory)Form ARS - Annual Report to Security HoldersNASDAQ:CNTACentessa Pharmaceuticals PLC
09/05/202407:00Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:CNTACentessa Pharmaceuticals PLC
23/04/202420:36GlobeNewswire Inc.Centessa Pharmaceuticals Announces Pricing of $100 Million Public Offering of American Depositary SharesNASDAQ:CNTACentessa Pharmaceuticals PLC
23/04/202415:17GlobeNewswire Inc.Centessa Pharmaceuticals Announces $100 Million Proposed Public Offering of American Depositary SharesNASDAQ:CNTACentessa Pharmaceuticals PLC
22/04/202406:00GlobeNewswire Inc.Centessa Pharmaceuticals Announces Open IND for ORX750; Proof-of-Concept Data in Sleep-Deprived Healthy Volunteers Planned for 2H 2024NASDAQ:CNTACentessa Pharmaceuticals PLC
28/03/202415:28GlobeNewswire Inc.Centessa Pharmaceuticals Reports Business Highlights and Financial Results for the Fourth Quarter and Full-Year 2023NASDAQ:CNTACentessa Pharmaceuticals PLC
22/02/202407:00GlobeNewswire Inc.Centessa Pharmaceuticals to Participate in TD Cowen’s 44th Annual Health Care ConferenceNASDAQ:CNTACentessa Pharmaceuticals PLC
09/02/202406:00GlobeNewswire Inc.Centessa Pharmaceuticals to Present Additional 52-Weeks of Continuous Treatment Data from Third Year (Part 5) of Ongoing Phase 2a Study of SerpinPC for the Treatment of Hemophilia at the 17th Annual Congress of the European Association for Haemophilia andNASDAQ:CNTACentessa Pharmaceuticals PLC
13/12/202307:00GlobeNewswire Inc.Centessa Pharmaceuticals to Present at the 42ⁿᵈ Annual J.P. Morgan Healthcare ConferenceNASDAQ:CNTACentessa Pharmaceuticals PLC
10/12/202311:05GlobeNewswire Inc.Centessa Pharmaceuticals Announces New Data from an Additional 52-Weeks of Continuous Treatment from Third Year (Part 5) of Ongoing Phase 2a Study of SerpinPC for the Treatment of HemophiliaNASDAQ:CNTACentessa Pharmaceuticals PLC
27/11/202315:15GlobeNewswire Inc.Anaptys Expands Immune Cell Modulator Pipeline with Exclusive License to BDCA2 Modulator Antibody Portfolio from Centessa PharmaceuticalsNASDAQ:CNTACentessa Pharmaceuticals PLC
13/11/202315:05GlobeNewswire Inc.Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Third Quarter of 2023NASDAQ:CNTACentessa Pharmaceuticals PLC
 Showing the most relevant articles for your search:NASDAQ:CNTA

Su Consulta Reciente

AMEX
SPY
SPDR S&P 500
COIN
AVAXUSD
Avalanche
FX
EURUSD
Euro vs US Dollar
USOTC
RHHBY
Roche (QX)
COIN
SOLUSD
Solana
NYSE
MCD
McDonalds
COIN
XRPUSD
Ripple
CCOM
US500
US 500
COIN
ETHUSD
Ethereum
NASDAQ
NVDA
NVIDIA
NYSE
MRK
Merck
NYSE
VZ
Verizon Communications
COIN
DOGEUSD
Dogecoin
NYSE
DIS
Walt Disney
NASDAQ
GOOGL
Alphabet
SPI
SP500
S&P 500
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

México
Empresa
Negocios
Popular
Obtener la aplicación
App Store
Google Play

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados